source
- Merck halts $2.7 billion BTK inhibitor program after negative phase 3 dataMerck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
- Big Pharma execs urge biotech firms to be transparent and patient to win dealsAt Fierce Biotech's London Life Sciences Week, representatives from five major pharmaceutical companies shared how they evaluate biotech partners. Bayer's head of business development warned that…